DFM STUDENT SYLLABUS - Flipbook - Page 42
Target Protein Pattern Analysis
528
S100B Antibodies
528
Claudin/Occludin Antibodies
528
Aquaporin-4 Antibodies
528
MMP Antibodies
528
Treatment Monitoring and Follow-Up
528
Expected Timeline for Antibody Resolution
528
Correlation with Clinical Improvement
529
Indicators for Treatment Modification
529
Long-Term Monitoring Strategy
529
Future Directions: Emerging Research and Applications
529
Advanced Biomarker Panels
529
Personalized Treatment Algorithms
529
Targeted Drug Delivery Systems
529
Regenerative Approaches
529
Microbiome-Based Interventions
530
Preventive Applications
530
Integration with Digital Health Technologies
530
Conclusion: The Clinical Value of Array 20 in Neurological Assessment
530
Early Detection
530
Mechanism Insights
530
Objective Monitoring
530
Comprehensive Assessment
531
Integration Potential
531
References
531
Comprehensive Guide to Cyrex Array 22: Clinical Applications and Integration with
Other Functional Testing
552
Introduction: The Immune-Gut Connection in SIBO and IBS
552
What is Cyrex Array 22?
553
Comprehensive Markers Evaluated by Array 22
553
Bacterial Toxins and Components
553
Intestinal Barrier Proteins
554
The Clinical Significance of Antibody Classes
554
41
